Updated:
Eurofins Scientific
Eurofins Scientific founder Gilles Martin built a global lab network and reinvests personal wealth in biotech and food-tech ventures.
Eurofins Scientific
Gilles Martin founded Eurofins Scientific in Nantes, France, in 1987, starting with four employees testing food and pharmaceutical products. The company went public in 1997 and has since become a global leader in bioanalytical testing, operating over 900 laboratories across 61 countries. Martin remains the largest individual shareholder and CEO, and his family office activity centers on reinvesting the dividends and personal wealth generated by the listed company's growth. Investment activity tracks closely with Martin's expertise in life sciences and diagnostic infrastructure. The office deploys capital across biotechnology, medical devices, agri-food technology, and laboratory real estate. Deal structure favors direct equity positions and co-investments alongside the Eurofins corporate M&A program, often providing follow-on capital to founders spinning out of the core Eurofins network. Geographic focus spans Europe, North America, and Asia-Pacific, with known commitments to early- and growth-stage companies developing novel genomic testing platforms and food-safety sensors. The exact size of the family office is not publicly disclosed, but Martin's reported net worth and Eurofins' $10B+ market capitalization suggest substantial private deployable capital. The office operates discreetly from Luxembourg without a separate public brand. Martin uses the same executive team that runs Eurofins to evaluate personal investments, blurring the line between corporate development and family-office due diligence. In 2023, Eurofins completed over 50 bolt-on acquisitions, a pace that implies a deep, permanent co-investment apparatus around Martin's personal book. Eurofins Scientific double-hats as a public company and the center of Martin's personal investment architecture. Unlike most family offices that wall off operating-company wealth through a distinct entity, Martin's structure keeps his private capital permanently interwoven with the corporate balance sheet and M&A pipeline. That gives the office access to proprietary deal flow in regulated laboratory markets — oncology diagnostics, environmental testing, forensics — that few pure financial investors can consistently reach.
General information
Firm type
Single Family Office
Year founded
1987
AUM
Undisclosed
Location
Region
Europe
Country
Luxembourg
City
Luxembourg
Corporate office
23, Val Fleuri, 1526 Luxembourg, Luxembourg
Principals
Gilles Martin
CEO and founder
Sector focus
Frequently asked questions
Who runs investment decisions at Eurofins Scientific's family office?
Gilles Martin makes investment decisions personally, relying on the same senior managers who run Eurofins Scientific's corporate M&A program. No separate family-office CIO or investment committee is publicly named. The Luxembourg-based structure operates through private holding vehicles that co-invest alongside the listed company.
How does Eurofins Scientific's family office source proprietary deal flow?
Deal flow comes primarily through the Eurofins laboratory network, which employs thousands of scientists and interacts with biotech startups, food producers, and diagnostic developers globally. Corporate M&A diligence on bolt-on acquisitions surfaces opportunities for Martin's personal capital to participate directly. The firm rarely participates in competitive auctions led by external bankers.
Is Eurofins Scientific structured as a single family office or does it operate more like a venture firm?
The office functions as a single family office but without a standalone brand or team separate from Eurofins Scientific. It does not raise third-party capital or operate as a venture firm. The structure is unusual in that the family's private investments move in tandem with corporate acquisitions rather than through a discrete family-office fund.
What investment stages does Eurofins Scientific's family office typically target?
Deals span early-stage to growth equity, with a preference for companies developing laboratory technologies, diagnostic platforms, and food-safety systems. The office often provides Series A and Series B capital to ventures that can later integrate into or sell to Eurofins Scientific. Late-stage pre-IPO positions are less common.
Which sectors does Eurofins Scientific's family office explicitly avoid?
No explicit exclusion list is published, but observed activity stays within life sciences, diagnostics, agri-food, and laboratory infrastructure. The office does not invest in consumer internet, fintech, enterprise SaaS, or heavy industry. The pattern reflects Martin's lifelong focus on bioanalytical sectors rather than a formal avoidance policy.
Where does the underlying wealth come from?
Gilles Martin's wealth derives from founding Eurofins Scientific and retaining significant equity through its 1997 IPO and subsequent expansion. Dividends and share sales from the publicly traded laboratory network fund the family office. Martin remains the largest individual shareholder. (per public record)
Does Eurofins Scientific's family office maintain philanthropic structures, and how are they separated?
No separate philanthropic foundation bearing the Eurofins name is publicly documented. Charitable giving appears to occur personally and through corporate social-responsibility programs of the listed company. The office's primary mission remains investment activity rather than structured philanthropy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: